Liver Cancer Registry at San Raffaele Hospital
Official title: San Raffaele Registry on Liver Cancer
Run by IRCCS San Raffaele · NCT07704489 · Data updated 2026-11-12
This project tests whether a large registry can help identify biomarkers and patterns in patients with liver cancer and biliary tract cancer who come to San Raffaele Hospital.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | October 20, 2021 |
| Main results expected | October 2050 |
| Study ends | October 2050 |
| Registry record updated | July 15, 2026 |
| Trial ID | NCT07704489 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with hepatocellular carcinoma or biliary tract cancer at any stage and undergoing any treatment, who can provide informed consent.
✕Probably not a fit
Patients whose cancer biology does not yield actionable biomarkers or who receive standard care unaffected by biomarker findings may derive no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center observational study that combines retrospective and prospective data collection to build a registry of primary liver cancer, including hepatocellular carcinoma and biliary tract carcinoma. The study will collect clinical, molecular, and biological samples over time to explore biomarkers that could aid patient management. Data will come from medical records and additional samples such as blood, saliva, stool, and tumor tissue, without changing standard care. Follow-up will last up to five years for enrolled participants. Analysis will look for correlations between clinical features and molecular characteristics to inform future research and care.
Why it matters
Potential benefit: If successful, the registry could improve understanding of liver cancer biology and identify potential biomarkers to guide treatment decisions.
How similar studies have gone: Registries and biobanks in liver cancer have shown potential in identifying biomarkers and informing care, though translational impact varies by center and data quality.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participant is willing and able to give informed consent for participation in the study. However, concerning the retrospective cohort, the large sample sizes needed and considering that the disease involved in this study affects elderly subjects with co-morbidities and presents a significant mortality rate based on the stage of the disease, deceased and untraceable patients will also be included. 2. ≥18 years of age. 3. Patients diagnosed with any subtype of biliary tract cancer (i.e. iCCA, pCCA, dCCA or GBC) at every stage and with all therapeutic indications. 4. Patients diagnosed with hepatocellular carcinoma at every stage and treated with all therapeutic options. Exclusion Criteria: 1\. Patients without diagnosis of hepatocellular carcinoma or biliary tract cancer (BTC).
Where it's running
-
IRCCS Ospedale San Raffaele
Milan, Italy Recruiting
Study contacts
- Study coordinator: Andrea Casadei Gardini, Medical Oncologist
- Email: CasadeiGardini.Andrea@hsr.it
- Phone: +390226437627
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effective Communication in VBAC Counseling
This study tests how clearly doctors and midwives explain VBAC options during prenatal visits and whether patients feel understood.
-
CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults
This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.
-
Photon-counting CT versus traditional CT for suspected coronary artery disease
This trial tests whether photon-counting CT can better diagnose obstructive CAD in people who need a coronary CTA than the standard energy-integrating detector CT.
-
Intensive 4-week postoperative multimodal rehab after proximal pancreatic surgery
This study tests whether a 4-week multimodal rehabilitation program can help adults who have severe complications after proximal pancreatic surgery recover better.
-
Engineered HMGB1 protein as a companion therapy for LAMA2-related muscular dystrophy
This study tests how existing patient samples from people with LAMA2-related muscular dystrophy can be used to explore a potential companion therapy using an engineered HMGB1 protein.
-
OCT in Neurological Practice: Use of Retinal Layers to Help Diagnose and Follow Neurological Diseases
This study tests whether optical coherence tomography (OCT) of the retina can help in diagnosing and tracking multiple sclerosis, Alzheimer's, Parkinson's, migraines, and other headaches compared with healthy people.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.